1-Aminomethyl-5-methoxyindane
| Clinical data | |
|---|---|
| Other names | AMMI |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO |
| Molar mass | 177.247 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
1-Aminomethyl-5-methoxyindane (AMMI), is a drug developed by a team led by David E. Nichols at Purdue University, which acts as a selective serotonin releasing agent (SSRA) and binds to the serotonin transporter (SERT) with similar affinity relative to DFMDA.